The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats

Asadur Rahman; Shamshad J. Sherajee; Kazi Rafiq; Hideki Kobara; Tsutomu Masaki; Daisuke Nakano; Takashi Morikawa; Yoshio Konishi; Masahito Imanishi; Akira Nishiyama

Journal of Pharmacological Sciences (Mar 2020)

The angiotensin II receptor-neprilysin inhibitor LCZ696 attenuates the progression of proteinuria in type 2 diabetic rats

Asadur Rahman,
Shamshad J. Sherajee,
Kazi Rafiq,
Hideki Kobara,
Tsutomu Masaki,
Daisuke Nakano,
Takashi Morikawa,
Yoshio Konishi,
Masahito Imanishi,
Akira Nishiyama

Affiliations

Asadur Rahman: Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Shamshad J. Sherajee: Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Kazi Rafiq: Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Hideki Kobara: Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Tsutomu Masaki: Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Daisuke Nakano: Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Takashi Morikawa: Division of Hypertension and Nephrology, Osaka General Hospital, Osaka, Japan
Yoshio Konishi: Division of Hypertension and Nephrology, Osaka General Hospital, Osaka, Japan
Masahito Imanishi: Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan
Akira Nishiyama: Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan; Corresponding author. Department of Pharmacology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan. Fax: +81 87 891 2126.

Journal volume & issue: Vol. 142, no. 3
pp. 124 – 126

Abstract

Read online

We examined the effects of the angiotensin receptor-neprilysin inhibitor LCZ696 on overt proteinuria and renal injury in type 2 diabetic Otsuka-Long- Evans-Tokushima-Fatty (OLETF) rats. Aged OLETF rats were also treated with either valsartan or valsartan plus hydralazine for comparison. LCZ696 caused greater attenuation of the progression of proteinuria than either valsartan alone or valsartan combined with hydralazine. Reduced glomerular injury and tubulointerstitial fibrosis were also observed in LCZ696-treated rats. Moreover, LCZ696 prevented increases in blood urea nitrogen (BUN) and creatinine levels. These data suggest that LCZ696 elicits a reno-protective effect against type 2 diabetes with overt proteinuria. Keywords: LCZ696, Proteinuria, Diabetic kidney disease (DKD)

Published in Journal of Pharmacological Sciences

ISSN: 1347-8613 (Print)
Publisher: Elsevier
Country of publisher: Japan
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://www.journals.elsevier.com/journal-of-pharmacological-sciences

About the journal